O 346
Latest Information Update: 25 Sep 2006
Price :
$50 *
At a glance
- Originator Novo Nordisk
- Class Insulins
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes insipidus
Most Recent Events
- 25 Sep 2006 Discontinued - Preclinical for Diabetes insipidus in Denmark (unspecified route)
- 14 Mar 2002 Preclinical trials in Diabetes insipidus in Denmark (unspecified route)